A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE001 (USA) · Dr. Reyes
consented 2022-03-17
Adverse events
Grade 2 Alopecia — outcome: RECOVERED/RESOLVED; onset 2022-04-08 (study day 3); relationship: not assessed
Grade 1 Anaemia — outcome: RECOVERED/RESOLVED; onset 2022-04-24 (study day 19); relationship: not assessed
Grade 2 Nausea — outcome: RECOVERED/RESOLVED; onset 2022-04-25 (study day 20); relationship: not assessed
Grade 2 Anaemia — outcome: RECOVERED/RESOLVED; onset 2022-04-26 (study day 21); relationship: Y
Grade 1 Fatigue — outcome: RECOVERED/RESOLVED; onset 2022-05-10 (study day 35); relationship: not assessed
Grade 2 Constipation — outcome: RECOVERED/RESOLVED; onset 2022-05-21 (study day 46); relationship: not assessed
Grade 1 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2022-05-28 (study day 53); relationship: N
Grade 1 Anaemia — outcome: RECOVERED/RESOLVED; onset 2022-06-03 (study day 59); relationship: not assessed
Data queries
No data queries.